Lexicon Pharmaceuticals | LXRX - Trade Debtors


Lexicon Pharmaceuticals reported $2.38M in Trade Debtors for its fiscal quarter ending in December of 2025.





Trade Debtors Change Date
Abbott USD 11.22B 655M Mar/2026
Acadia Pharmaceuticals USD 148.38M 153K Mar/2026
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
Akebia Therapeutics USD 47.03M 19.19M Dec/2025
Alnylam Pharmaceuticals USD 912.74M 28.78M Jun/2026
AstraZeneca USD 18.86B 972M Jun/2026
BioMarin Pharmaceutical USD 903.91M 4.3M Mar/2026
Coherus Biosciences USD 18.42M 232.08M Dec/2025
Eli Lilly USD 21.18B 1.02B Mar/2026
Halozyme Therapeutics USD 457.99M 16.72M Mar/2026
Illumina USD 764M 26M Jun/2026
Insmed USD 178.55M 37.7M Mar/2026
Ironwood Pharmaceuticals USD 81.89M 5.68M Dec/2024
J&J USD 22.54B 1.21B Mar/2026
Lexicon Pharmaceuticals USD 2.38M 50K Dec/2025
MacroGenics USD 10.42M 2.95M Mar/2026
MannKind USD 28.14M 10.23M Mar/2026
Merck USD 11.78B 345M Dec/2025
Moderna USD 17M 54M Jun/2026
Novartis USD 9.85B 252M Jun/2026
PTC Therapeutics USD 219.92M 38.3M Mar/2026
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Sarepta Therapeutics USD 547.91M 149.68M Mar/2026
Thermo Fisher Scientific USD 9.45B 247M Jun/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
United Therapeutics USD 312M 38.2M Mar/2026
Vanda Pharmaceuticals USD 47.1M 4.35M Dec/2024